Journal article · 2025 · Open access

Comparative risk of incident malignancies in rheumatoid arthritis patients treated with Janus kinase inhibitors or bDMARDs: observational data from the German RABBIT register

Martin K.-H. Schäfer, Alina Purschke, Vera Zietemann, T. Rudi, Yvette Meißner, Adrian Richter, Sylvia Berger, Karin Rockwitz, Klaus Krüger, Karl Matthias Schneider, Anne C. Regierer, Anja Strangfeld

Annals of the Rheumatic Diseases, 84(11), 1779–1790 · Published 25 June 2025 · DOI 10.1016/j.ard.2025.05.014

Open PDFView at the publisherCite this paper

In brief

“Comparative risk of incident malignancies in rheumatoid arthritis patients treated with Janus kinase inhibitors or bDMARDs: observational data from the German RABBIT register” is a 2025 journal article by Martin K.-H. Schäfer and 11 co-authors, published in Annals of the Rheumatic Diseases. OpenAlex counts 32 citations as of 19 November 2026. It is open access under a CC BY-NC licence: the full text is free to read at Annals of the Rheumatic Diseases.

Citations
32
Most cited in
2026 (24)
Field-weighted impact
14.65
References
47
Authors
12

Abstract

OBJECTIVES: To estimate the effects of Janus kinase inhibitors (JAKis) vs biologic disease-modifying antirheumatic drugs (bDMARDs) on the risk of incident malignancies (excluding nonmelanoma skin cancer) in patients and patient subgroups with rheumatoid arthritis. METHODS: Episodes of disease-modifying antirheumatic drug (DMARD) treatment initiated between January 2017 and December 2020 and followed up to June 2024 in RABBIT, the German register for the long-term observation of therapy with biologics and targeted disease-modifying antirheumatic drugs in adult patients with rheumatoid arthritis, were analysed. Incidence rates (IRs) per 1000 patient-years with 95% CIs were calculated, and incident malignancy risk was estimated as hazard ratios (HRs) by inverse probability weighted adjusted Cox models. RESULTS: Among 2285 JAKi and 4259 bDMARD treatment episodes, 88 and 135 malignancies occurred, respectively. JAKi treatments were dominated by baricitinib and tofacitinib, while most bDMARD treatments comprised tumour necrosis factor inhibitors. IRs were 11.6 (95% CI: 9.3, 14.3) in JAKi- and 8.9 (95% CI: 7.4, 10.5) in bDMARD-treated groups. The adjusted HR comparing JAKis with bDMARDs was 1.40 (95% CI: 1.09, 1.80). An increase in the malignancy risk for JAKi vs bDMARD treatment could only be observed in treatment episodes lasting longer than 16 months. The risk appeared higher in some subgroups of patients, including those who started treatment aged ≥60 years, patients with ≥3 prior conventional synthetic DMARD treatments, and patients with high disease activity. CONCLUSIONS: In this German observational cohort study, an overall small increase in malignancy risk for JAKi vs bDMARD treatment was observed, with more pronounced risks in some subgroups of patients. The observed risk should be carefully counterbalanced to the known malignancy risk associated with insufficient disease control.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Schäfer, M. K.-H., Purschke, A., Zietemann, V., Rudi, T., Meißner, Y., Richter, A., Berger, S., Rockwitz, K., Krüger, K., Schneider, K. M., Regierer, A. C., & Strangfeld, A. (2025). Comparative risk of incident malignancies in rheumatoid arthritis patients treated with Janus kinase inhibitors or bDMARDs: observational data from the German RABBIT register. Annals of the Rheumatic Diseases, 84(11), 1779–1790. https://doi.org/10.1016/j.ard.2025.05.014

MLA 9

Schäfer, Martin K.-H., et al. “Comparative risk of incident malignancies in rheumatoid arthritis patients treated with Janus kinase inhibitors or bDMARDs: observational data from the German RABBIT register.” Annals of the Rheumatic Diseases, vol. 84, no. 11, 2025, pp. 1779–1790. https://doi.org/10.1016/j.ard.2025.05.014.

Chicago

Schäfer, Martin K.-H., Alina Purschke, Vera Zietemann, T. Rudi, Yvette Meißner, Adrian Richter, Sylvia Berger, et al. 2025. “Comparative risk of incident malignancies in rheumatoid arthritis patients treated with Janus kinase inhibitors or bDMARDs: observational data from the German RABBIT register.” Annals of the Rheumatic Diseases 84 (11): 1779–1790. https://doi.org/10.1016/j.ard.2025.05.014.

Harvard

Schäfer, M. K.-H. et al. (2025) ‘Comparative risk of incident malignancies in rheumatoid arthritis patients treated with Janus kinase inhibitors or bDMARDs: observational data from the German RABBIT register’, Annals of the Rheumatic Diseases, 84(11), pp. 1779–1790. doi:10.1016/j.ard.2025.05.014.

IEEE

M. K.-H. Schäfer et al., “Comparative risk of incident malignancies in rheumatoid arthritis patients treated with Janus kinase inhibitors or bDMARDs: observational data from the German RABBIT register,” Annals of the Rheumatic Diseases, vol. 84, no. 11, pp. 1779–1790, 2025, doi: 10.1016/j.ard.2025.05.014.

BibTeX

@article{schafer2025comparative,
  title     = {{Comparative risk of incident malignancies in rheumatoid arthritis patients treated with Janus kinase inhibitors or bDMARDs: observational data from the German RABBIT register}},
  author    = {Schäfer, Martin K.-H. and Purschke, Alina and Zietemann, Vera and Rudi, T. and Meißner, Yvette and Richter, Adrian and Berger, Sylvia and Rockwitz, Karin and Krüger, Klaus and Schneider, Karl Matthias and Regierer, Anne C. and Strangfeld, Anja},
  journal   = {Annals of the Rheumatic Diseases},
  year      = {2025},
  volume    = {84},
  number    = {11},
  pages     = {1779--1790},
  doi       = {10.1016/j.ard.2025.05.014},
  url       = {https://doi.org/10.1016/j.ard.2025.05.014}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202411
202577
20262424

Its field-weighted citation impact is 14.65: it has been cited 14.65 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies

  • rheumatoid arthritis
  • JAK inhibitors
  • biologic DMARDs
  • baricitinib
  • tofacitinib
  • tumor necrosis factor inhibitors
  • drug safety
  • disease activity

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Schäfer, M. K.-H., Purschke, A., Zietemann, V., Rudi, T., Meißner, Y., Richter, A., Berger, S., Rockwitz, K., Krüger, K., Schneider, K. M., Regierer, A. C., & Strangfeld, A. (2025). Comparative risk of incident malignancies in rheumatoid arthritis patients treated with Janus kinase inhibitors or bDMARDs: observational data from the German RABBIT register. Annals of the Rheumatic Diseases, 84(11), 1779–1790. https://doi.org/10.1016/j.ard.2025.05.014

How many times has this paper been cited?

32 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Annals of the Rheumatic Diseases: sign in and open the PDF from this page.

Who wrote this paper?

Martin K.-H. Schäfer, Alina Purschke, Vera Zietemann, T. Rudi, Yvette Meißner, Adrian Richter, Sylvia Berger, Karin Rockwitz, Klaus Krüger, Karl Matthias Schneider, Anne C. Regierer, Anja Strangfeld.

What is the DOI of this paper?

10.1016/j.ard.2025.05.014, permanently at https://doi.org/10.1016/j.ard.2025.05.014. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.